BioSante has provided positive safety data in its ongoing LibiGel phase III clinical development program. The phase III Cardiovascular and Breast Cancer Safety Study is a randomized, double-blind,
Response Genetics has posted increase in total revenue by 4% to $1.9m for the second quarter, 2009, as compared to $1.8m for the same period last year. The
Interleukin Genetics has posted revenue from continuing operations for the three months ended June 30, 2009 at $0.2m, compared to $0.5m for the same period in the prior
Cyanotech has reported increase in revenues by 9% to $4m, for the first quarter of 2010, compared to revenues of $3.7m for the first quarter of 2009. Gross
Hisamitsu has reported the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act) on 12 August, 2009, with respect
Oxygen has received approval to begin a phase II, dose escalation, clinical trial in Switzerland for use of Oxycyte in traumatic brain injury (TBI). The company has named
Celesio has reported an increase in revenue by 2% and EBITDA by 3.5% in local currency in the first half of 2009, as compared to the previous year.
Amgen has issued the statement on the outcome of meeting with the FDA’s Advisory Committee for Reproductive Health Drugs (ACRHD), to review the potential use of Prolia (denosumab).
OncoGenex has reported the first patient dosing in an open label, dose-escalation, phase 1 clinical trial, evaluating OGX-427 when administered directly into the bladder in patients with bladder
Pacgen has completed the acquisition of Xphase Pharmaceuticals (Xphase), following the approval of the TSX Venture Exchange. Pursuant to a share purchase agreement with Xphase and its shareholders,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.